Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback